MyFinsight
Home
Blog
About
Contact
Download
Download image
something is missing
$188,880K
Proceeds from issuance of
common stock pursuant...
$20,218K
Proceeds from stock
option exercises
$4,055K
Net cash provided by
financing activities
$24,272K
Canceled cashflow
$188,881K
Net increase
(decrease) in cash and cash...
-$60,142K
Canceled cashflow
$24,272K
Maturities of marketable
securities
$302,500K
Stock-based compensation
$6,548K
Accrued interest
receivable
-$289K
Depreciation and
amortization
$6K
Proceeds from issuance of
common stock pursuant...
-$188,880K
Payment of shelf
offering costs
$1K
Net cash used in
investing activities
-$44,943K
Net cash used in
operating activities
-$39,471K
Canceled cashflow
$302,500K
Canceled cashflow
$6,843K
Purchases of marketable
securities
$347,443K
Net loss
-$39,339K
Accretion of discount on
held-to-maturity securities
$4,625K
Prepaid, other current
assets, and other assets
$1,948K
Accounts payable and
accrued liabilities
-$402K
Back
Back
Cash Flow
source: myfinsight.com
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)